For this annual special report, which is in its 29th year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.
The top pharmaceutical companies are blurring the lines with biotech and have been engaging in many collaborations, acquisitions, and restructuring plans in the past year.
With not one but two record-shattering product launches that transformed the treatment of hepatitis C, Gilead more than doubled its revenue in a single year, earning its place as Med Ad News’ Company of the Year.
Med Ad News spoke with Paul Carter, Gilead’s executive VP of commercial operations, regarding the success of Sovaldi and Harvoni as well as the company’s vision of the future of biopharmaceuticals.
Amgen has been an independent biotech leader for years with an established array of blockbuster products, and now the company’s next wave of promising medicines is making its mark.
To accelerate the former, AstraZeneca has been engaging in a lot of the latter, as the company makes deals with other pharma and biotech companies as well as PatientsLikeMe.
Between new approvals, new drug applications and research collaborations with other companies, most of the big news about Bristol-Myers Squibb in the past year has concerned the company’s newest immuno-oncologic drug.
A three-part transaction with Novartis is anticipated to transform the future shape of GlaxoSmithKline, making the company more balanced and providing better opportunity for broadly based sales growth.
J&J’s innovation strategy has created an industry-leading pipeline and a cycle of success that positions the company for continued growth.
The leaders at Lilly knew that revenue would be bottoming out last year; with several recent new product approvals and more brewing in the pipeline, things are looking up in Indianapolis.